TScan Therapeutics snags over $48 mln Series B

TScan Therapeutics, which designs therapies that reprogram a patient’s own T cells, has raised over $48 million in Series B financing. TScan’s backers included Bessemer Venture Partners, Google Ventures, Longwood Fund and Novartis Venture Fund.

Source: Press Release